Specimens: | 500 µl Serum (s) |
Preanalytics/Notes: | Information: Screening for heparin-induced thrombocytopenia type II (HIT type II) |
Set-up: | on demand |
Duration: | 3 days |
Indication/Significance: |
|
Interpretation: |
The formation of more… The formation of antibodies against platelet factor (PF)4-heparin complexes, associated with a thrombocytopenia and/or thromboembolic complications under heparin therapy is referred to as immunological HIT or HIT II. HIT type I is to be distinguished from this as it is characterised by a reversible low platelet count not of immunological origin without coagulation activation. The formation of IgG antibodies against PF4-heparin complexes is the cause of the threatening HIT. This complex of IgG antibodies and PF4-heparin leads to a distinct platelet activation and subsequently to thrombin formation which results in an excessive coagulation activity. Paradoxically a disseminated formation of thrombi thus occurs despite anticoagulation and thrombocytopenia. If HIT antibodies cannot be detected, HIT can be ruled out with a high degree of certainty. In the case of a detection of weakly positive or borderline antibodies, the inhibition capacity of the antibody reaction is tested by adding heparin (so-called heparin inhibition). A confirmatory analysis is also possible by means of a functional test, e.g. the HIPA test (heparin-induced platelet activation test). |
both sex | ||
---|---|---|
not detectable |
Die Kosten werden für den i. d. R. genutzten 1,15-fachen GOÄ-Satz dargestellt. Wird die Untersuchung nicht in Ihrem regionalen Labor durchgeführt, erfolgt die Analyse in dem Labor, das im Leistungsverzeichnis genannt ist. In diesem Fall gilt der dort für die Untersuchung angegebene Preis.